Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are identified as a subset (4-12%) of EGFR mutation-positive non-small cell lung cancer (NSCLC) and are the third most common category of EGFR activating mutations [1 –3]. EGFR exon 20 insertion mutations are heterogeneous at the molecular level but can be characterized as in-frame duplications (dup) or insertions (ins), or deletion/insertion (delins) mutations. EGFR exon 20 insertions are EGFR driver mutations that exhibit intrinsic resistance to first and sec ond generation EGFR tyrosine kinase inhibitors (TKIs) with overall response rates of only 3-8% [1,3].

Source: Lung Cancer - December 19, 2019 Category: Cancer & Oncology Authors: B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen Source Type: research